Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 67 points (0.4%) at 16,436 as of Friday, Aug. 8, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,992 issues advancing vs. 961 declining with 169 unchanged. The Health Care sector currently sits up 0.3% versus the S&P 500, which is up 0.4%. Top gainers within the sector include Air Methods ( AIRM), up 11.3%, Taro Pharmaceutical Industries ( TARO), up 3.6%, Allergan ( AGN), up 2.7%, Valeant Pharmaceuticals International ( VRX), up 1.4% and Humana ( HUM), up 1.1%. On the negative front, top decliners within the sector include Salix Pharmaceuticals ( SLXP), down 5.4%, Pharmacyclics ( PCYC), down 3.2%, AstraZeneca ( AZN), down 2.8%, Mylan ( MYL), down 1.6% and HCA Holdings ( HCA), down 1.3%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Vertex Pharmaceuticals is up $1.60 (1.9%) to $86.34 on light volume. Thus far, 418,696 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $85.18-$86.51 after having opened the day at $85.20 as compared to the previous trading day's close of $84.74. Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $20.7 billion and is part of the drugs industry. Shares are up 14.1% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Vertex Pharmaceuticals as a hold. Among the primary strengths of the company is its solid stock performance, considering both the consistency and magnitude of the price movement over time. At the same time, however, we also find weaknesses including feeble growth in the company's earnings per share, unimpressive growth in net income and disappointing return on equity. Get the full Vertex Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.